Exhibit 99.1 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 31, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2024. Total revenues in the second quarter of 2024 grew 20 percent year-over-year to $714.9 million, compared to $596.5 million in the second quarter of 2023. Key financial highlights include (dollars in millions, except per share data): United Therapeutics Corporation Reports Second ...

Part I. Financial Information | --- | --- | --- | --- | --- | |-------------------------------------|-------|----------------------------|-----------------------------|----------------------| | Due within one year | $ | Amortized Cost \n 1,632.2 | As of June 30, 2024 \n \n$ | Fair Value \n1,622.1 | | Due in one to three years | | 1,337.2 | | 1,330.4 | | Total | $ | 2,969.4 | $ | 2,952.5 | As of June 30, 2024 and December 31, 2023, we maintained non-controlling equity investments in privately-held companies ...

Core Insights - The article emphasizes the importance of combining a strong Zacks Rank with a high Value grade to identify great value stocks [1] - It highlights traditional metrics that value investors use to find undervalued stocks [2] Company Comparisons - United Therapeutics (UTHR) has a forward P/E ratio of 13.21 and a PEG ratio of 1.43, indicating a favorable valuation compared to Catalent (CTLT), which has a forward P/E of 49.28 and a PEG ratio of 1.69 [3][4] - UTHR's P/B ratio is 2.73, while CTLT's P/B ratio is 2.90, further supporting UTHR's superior valuation metrics [6] - UTHR is rated with a Zacks Rank of 2 (Buy), while CTLT has a Zacks Rank of 5 (Strong Sell), indicating a better earnings outlook for UTHR [8] Valuation Metrics - The article discusses various key metrics used in the Value category, including P/E ratio, P/S ratio, earnings yield, and cash flow per share, which are essential for identifying undervalued companies [9]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. It also includes access to the Zacks Style Scores. The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest ...

Core Viewpoint - The analysis suggests that United Therapeutics (UTHR) is currently a more attractive investment option compared to Catalent (CTLT) for value investors, based on Zacks Rank and various valuation metrics [2][3][6]. Group 1: Zacks Rank and Earnings Outlook - UTHR has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while CTLT has a Zacks Rank of 5 (Strong Sell), suggesting a negative outlook [3]. - The emphasis on positive earnings estimate revisions indicates that UTHR is likely experiencing an improvement in its earnings outlook compared to CTLT [3]. Group 2: Valuation Metrics - UTHR has a forward P/E ratio of 13.17, significantly lower than CTLT's forward P/E of 49.27, indicating that UTHR may be undervalued relative to CTLT [8]. - UTHR's PEG ratio is 1.43, while CTLT's PEG ratio is 1.69, suggesting that UTHR offers better value when considering expected earnings growth [8]. - UTHR has a P/B ratio of 2.72, compared to CTLT's P/B of 2.90, further supporting the notion that UTHR is a more attractive investment [5]. Group 3: Value Grades - UTHR has received a Value grade of B, while CTLT has a Value grade of D, indicating that UTHR is viewed as a better value investment based on key financial metrics [9].

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all. However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cuttingedge growth stocks. Studies have shown that stocks with the best gro ...

Given these factors, it shouldn't be surprising that UTHR is a #2 (Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep United Therapeutics on your short list. Earnings Outlook The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have re ...

Core Viewpoint - United Therapeutics (UTHR) is currently viewed as a more attractive investment option compared to Catalent (CTLT) for value investors, based on various valuation metrics and analyst outlooks [2][5]. Valuation Metrics - UTHR has a P/B ratio of 2.67, while CTLT has a P/B ratio of 2.89, indicating that UTHR is relatively undervalued compared to CTLT [4]. - The forward P/E ratio for UTHR is 12.93, significantly lower than CTLT's forward P/E of 49.05, suggesting UTHR is more favorably priced [8]. - UTHR's PEG ratio stands at 1.40, while CTLT's PEG ratio is 1.68, further supporting UTHR's position as a better value investment [8]. Analyst Outlook - UTHR holds a Zacks Rank of 2 (Buy), reflecting a positive earnings estimate revision activity, whereas CTLT has a Zacks Rank of 5 (Strong Sell), indicating a less favorable outlook [2][5]. - UTHR has a Value grade of B, while CTLT has a Value grade of D, highlighting the relative strength of UTHR in terms of value metrics [9].

Core Viewpoint - United Therapeutics has shown significant stock performance, with an 11.6% increase over the past month and a 46.2% rise since the beginning of the year, outperforming both the Zacks Medical sector and the Zacks Medical - Drugs industry [1][2]. Financial Performance - For the current fiscal year, United Therapeutics is projected to achieve earnings of $24.85 per share on revenues of $2.71 billion, reflecting a 25.44% increase in EPS and a 16.46% increase in revenues [2]. - The next fiscal year forecasts earnings of $27.25 per share on revenues of $2.85 billion, indicating a year-over-year change of 9.65% in EPS and 5.16% in revenues [2]. Valuation Metrics - The stock trades at 12.9 times the current fiscal year EPS estimates, below the peer industry average of 15.2 times [7]. - On a trailing cash flow basis, the stock trades at 14.6 times, compared to the peer group's average of 8.7 times [7]. - The PEG ratio stands at 1.4, which does not position the company among the top value stocks [7]. Style Scores - United Therapeutics has a Value Score of B, with Growth and Momentum Scores both rated A, resulting in a combined VGM Score of A [9]. Zacks Rank - The stock holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts [10]. - The recommendation suggests that stocks with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B are favorable, indicating potential for further gains for United Therapeutics [11]. Earnings Surprises - The company has a strong track record of positive earnings surprises, having met or exceeded earnings consensus estimates in the last four quarters [12]. - In the latest earnings report on May 1, 2024, United Therapeutics reported an EPS of $6.17, surpassing the consensus estimate of $5.63 [12].

United Therapeutics (UTHR) announced full enrolment in the phase III TETON 2 study evaluating a nebulized version of Tyvaso (treprostinil) in patients with idiopathic pulmonary fibrosis (IPF), a scarring disease of the lungs. The TETON 2 study is now enrolled with a total of 597 patients. Top-line data from this study is expected in second-half 2025. The FDA has already approved Tyvaso as an inhalation solution (nebulized) and dry powder inhaler (DPI) for treating pulmonary arterial hypertension (PAH) and p ...